EMEA-001272-PIP02-13-M01

Key facts

Invented name
Vidaza
Active substance
azacitidine
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0217/2015
PIP number
EMEA-001272-PIP02-13-M01
Pharmaceutical form(s)
  • Powder for suspension for injection
  • Powder for solution for infusion
Condition(s) / indication(s)
  • Treatment of myelodysplastic syndrome (including juvenile myelomonocytic leukaemia)
  • Treatment of acute myeloid leukaemia
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Celgene Europe Ltd
Switzerland
Tel. +41 3272 98500
Fax +41 3272 98508
E-mail: medinfo.intl@celgene.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating